Cargando…

Excision of latent HIV-1: CRISPR technology overcomes viral strain diversity

Detalles Bibliográficos
Autor principal:	Bunnell, Bruce A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628217/ https://www.ncbi.nlm.nih.gov/pubmed/34839262 http://dx.doi.org/10.1016/j.ebiom.2021.103720

Ejemplares similares

The evolving CRISPR technology
por: Yan, Meng, et al.
Publicado: (2019)

Quantitation of the latent HIV-1 reservoir from the sequence diversity in viral outgrowth assays
por: Poon, Art F. Y., et al.
Publicado: (2018)

Latent IgA Deposition in Donated Kidneys in an Ethnically Diverse Population
por: Sofue, Tadashi
Publicado: (2020)

In defense of phage: Viral suppressors of CRISPR-mediated adaptive immunity in bacteria
por: Wiedenheft, Blake
Publicado: (2013)

Structures of Reverse Transcriptase Pre- and Post-Excision Complexes Shed New Light on HIV-1 AZT Resistance
por: Scott, Walter A.
Publicado: (2011)

HIV and Aging: Overcoming Challenges in Existing HIV Guidelines to Provide Patient-Centered Care for Older People with HIV
por: Sangarlangkarn, Aroonsiri, et al.
Publicado: (2021)

Overcoming the COVID-19 Pandemic in Indonesia: A Science, technology, and innovation (STI) policy perspective
por: Putera, Prakoso Bhairawa, et al.
Publicado: (2022)

CRISPR/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus
por: Panfil, Amanda R., et al.
Publicado: (2018)

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA
por: Zhu, Weijun, et al.
Publicado: (2015)

Overcoming challenges across the HIV care continuum in the Asia-Pacific region: expert recommendations
por: Choi, Jun Yong, et al.
Publicado: (2023)

The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape
por: Darcis, Gilles, et al.
Publicado: (2019)

FISHing Out the Hidden Enemy: Advances in Detecting and Measuring Latent HIV-Infected Cells
por: Prasad, Vinayaka R., et al.
Publicado: (2017)

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
por: Ebina, Hirotaka, et al.
Publicado: (2013)

A step forward understanding HIV-1 diversity
por: Smyth, Redmond P., et al.
Publicado: (2016)

Dual role of TRBP in HIV replication and RNA interference: viral diversion of a cellular pathway or evasion from antiviral immunity?
por: Gatignol, Anne, et al.
Publicado: (2005)

PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread
por: Tang, Xiaolong, et al.
Publicado: (2015)

Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir
por: Roychoudhury, Pavitra, et al.
Publicado: (2018)

CRISPR/Cas9: a double-edged sword when used to combat HIV infection
por: Liang, Chen, et al.
Publicado: (2016)

Technological Diversity for Mobility
por: Raßmann, Alexander
Publicado: (2021)

Deciphering How HIV‐1 Intersubtype Recombination Shapes Viral Fitness and Disease Progression
por: Turk, Gabriela, et al.
Publicado: (2015)

CRISPRing into the woods
por: Tsai, Chung-Jui, et al.
Publicado: (2015)

Addressing challenges in the clinical applications associated with CRISPR/Cas9 technology and ethical questions to prevent its misuse
por: Kang, Xiang Jin, et al.
Publicado: (2017)

Viral and Latent Reservoir Persistence in HIV-1–Infected Patients on Therapy
por: Kim, Hwijin, et al.
Publicado: (2006)

Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene
por: Gergen, Janina, et al.
Publicado: (2018)

Zinc-Finger Nucleases Induced by HIV-1 Tat Excise HIV-1 from the Host Genome in Infected and Latently Infected Cells
por: Ji, Haiyan, et al.
Publicado: (2018)

Interchangeability of Biosimilars: Overcoming the Final Hurdles
por: Barbier, Liese, et al.
Publicado: (2021)

Overcoming physical barriers in cancer therapy
por: Beyer, Ines, et al.
Publicado: (2013)

A Strong Case for Viral Genetic Factors in HIV Virulence
por: Müller, Viktor, et al.
Publicado: (2011)

Anti-CRISPR Phages Cooperate to Overcome CRISPR-Cas Immunity
por: Landsberger, Mariann, et al.
Publicado: (2018)

DRUG REPURPOSING—Overcoming the translational hurdles to clinical use
por: Martin, Jennifer H., et al.
Publicado: (2019)

The updated strategy to overcome new challenge: Omicron variant (B.1.1.529) pandemic
por: Ri, HyokJu, et al.
Publicado: (2022)

Relevance of multiply spliced HIV-1 RNA measurement in assessing the efficacy of viral latency-reversing strategies
por: Doria, Margherita
Publicado: (2021)

Excision of Integrated Human Herpesvirus 6A Genomes Using CRISPR/Cas9 Technology
por: Aimola, Giulia, et al.
Publicado: (2023)

Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex
por: Saayman, Sheena M, et al.
Publicado: (2016)

Overcoming bias and systematic errors in next generation sequencing data
por: Taub, Margaret A, et al.
Publicado: (2010)

Dormancy antigens as biomarkers of latent tuberculosis infection
por: Latorre, Irene, et al.
Publicado: (2015)

The latent cytomegalovirus decreases telomere length by microcompetition
por: Polansky, Hanan, et al.
Publicado: (2015)

Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy
por: Rong, Libin, et al.
Publicado: (2009)

Overcoming viral escape with vaccines that generate and display antigen diversity in vivo
por: García-Quintanilla, Albert
Publicado: (2007)

Implications of HIV-1 Nef for “Shock and Kill” Strategies to Eliminate Latent Viral Reservoirs
por: Kuang, Xiaomei T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hq30dj03ji1noinlqdl5metajp